Equivalence of the GeneXpert System and GeneXpert Omni System for tuberculosis and rifampicin resistance detection.
PLoS One
; 16(12): e0261442, 2021.
Article
in English
| MEDLINE | ID: covidwho-1593549
ABSTRACT
A laboratory validation study was conducted to assess the equivalence of Xpert MTB/RIF Ultra testing on the GeneXpert System and the GeneXpert Omni System ('Omni') for tuberculosis and rifampicin resistance. High concordance of the two devices was demonstrated for well-characterized clinical samples as well as control materials, with controls tested on Omni at normal and challenging environmental conditions (i.e. 35°C, 90% relative humidity). Equivalence of the Cts for all probes was also shown. Equivalence was demonstrated for the Omni and GeneXpert devices for tuberculosis and rifampicin resistance detection for a diverse range of clinical specimens and environmental conditions.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Tuberculosis, Pulmonary
/
Tuberculosis, Multidrug-Resistant
/
Point-of-Care Testing
/
Antibiotics, Antitubercular
/
Mycobacterium tuberculosis
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
PLoS One
Journal subject:
Science
/
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Journal.pone.0261442
Similar
MEDLINE
...
LILACS
LIS